Guanosine dose-dependently reduced 5-HTP-induced wet dog shakes (WDS) and other Serotonin Syndromes

Lokzo

Member
Forum Supporter
Joined
Mar 26, 2016
Messages
2,123
Location
Melbourne
Schizophrenia is a serious mental disorder characterized by hallucinations, delusions, and extremely disordered thinking and behavior. There are several hypotheses of pathogenesis in schizophrenia: dopaminergic, glutamatergic, or serotonergic hyperfunction. Guanosine reportedly protects the central nervous system by modulating the glutamatergic system. Thus, we assumed that guanosine may exert a positive effect on the pathophysiology of schizophrenia. Herein, we demonstrated that guanosine significantly reduced MK-801-induced hyperlocomotion and stereotyped behaviors, but showed no effect on hyperlocomotion induced by d-amphetamine, indicating that guanosine may directly affect the glutamatergic system. Guanosine dose-dependently reduced 5-HTP-induced wet dog shakes (WDS) and other serotonin syndromes (SS) behaviors, indicating that it might block serotonin 5-HT1A or 5-HT2A receptors. Finally, we confirm that that guanosine modulates serotonin 5-HT1A and 5-HT2A receptors and it might be anti-schizophrenic partly through pertussis toxin-sensitive Gi/o-coupled PI3K/Akt signaling. Collectively, this study provides possible compounds and mechanisms for therapeutic effects on schizophrenia.

@haidut - Have you experimented with this molecule?
 

Grapelander

Member
Joined
Mar 26, 2019
Messages
1,297
Location
Sonoma County
Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders
Evidence from rodent and cell models show a number of neurotrophic and neuroprotective effects of guanosine preventing deleterious consequences of seizures, spinal cord injury, pain, mood disorders and aging-related diseases, such as ischemia, Parkinson’s and Alzheimer’s diseases.

Guanosine prevents oxidative damage and glutamate uptake impairment induced by oxygen/glucose deprivation in cortical astrocyte cultures: involvement of A 1 and A 2A adenosine receptors and PI3K, MEK, and PKC pathways
We evaluated if the neuroprotective effect of guanosine is also observed in cultured cortical astrocytes subjected to oxygen/glucose deprivation (OGD) and reoxygenation. Guanosine treatment prevented these OGD-induced damaging effects.
 
OP
Lokzo

Lokzo

Member
Forum Supporter
Joined
Mar 26, 2016
Messages
2,123
Location
Melbourne
Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders
Evidence from rodent and cell models show a number of neurotrophic and neuroprotective effects of guanosine preventing deleterious consequences of seizures, spinal cord injury, pain, mood disorders and aging-related diseases, such as ischemia, Parkinson’s and Alzheimer’s diseases.

Guanosine prevents oxidative damage and glutamate uptake impairment induced by oxygen/glucose deprivation in cortical astrocyte cultures: involvement of A 1 and A 2A adenosine receptors and PI3K, MEK, and PKC pathways
We evaluated if the neuroprotective effect of guanosine is also observed in cultured cortical astrocytes subjected to oxygen/glucose deprivation (OGD) and reoxygenation. Guanosine treatment prevented these OGD-induced damaging effects.

Yes, I think it has potential, but it isn't being sold in supplemental form. There must be a big reason.
 

Similar threads

Back
Top Bottom